RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
Revitty (RVTY) Q3 2024 Earnings Call Transcript
Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt Sykes - Goldman Sachs Brandon Couillard - Wells Fargo Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Hello everyone and welcome to Revitty's third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today.
Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.
Revvity cuts 2024 revenue forecast amid biotech spending slowdown
Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.
Revvity to Report Q3 Earnings: What's in Store for the Stock?
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.
Reasons to Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
MD or RVTY: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?
